Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

More questions than answers as Canada’s immunity task force releases initial results

Terry Murray
CMAJ August 10, 2020 192 (32) E933-E934; DOI: https://doi.org/10.1503/cmaj.1095887
Terry Murray
Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Initial results of a study of blood donors have provided a first glimpse into how many Canadian adults have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19).

The study, conducted by Canadian Blood Services and Canada’s COVID-19 Immunity Task Force, found that fewer than 1% of 10 000 samples tested positive for antibodies to the virus, indicating past infection with SARS-CoV-2.

These results are both good and bad news, says immunity task force co-chair Dr. Catherine Hankins.

The good news is that the public health measures taken by Canadians — from staying home to wearing masks — seem to have slowed spread of the virus, and Canada’s case-fatality rate is likely much lower than initially thought.

Previously, based on the number of confirmed cases of COVID-19, “we had what appeared to be an extraordinarily high case-fatality rate that was around 8%,” Hankins explains.

However, the new findings would seem to confirm that there are several more infections in the community for every confirmed case of COVID-19. If one in 100 Canadians have been infected with the virus, Canada’s true case-fatality rate is likely “quite a bit lower and more in line with what’s being seen elsewhere… around 1%,” Hankins says.

The bad news is that a population seroprevalence of around 1% is a far cry from the 60% to 70% considered necessary for herd immunity.

“We’ve had a major pandemic come through this country and we’re nowhere near what scientists believe is required for herd immunity,” Hankins says. “So, the vast majority of us remain susceptible to this.”

Figure1

One in 100 Canadians may have been infected with SARS-CoV-2 in the first wave of the pandemic, according to the initial results of a study of blood donors.

Image courtesy of iStock.com/Orbon Alija

This is not the end of the story, though. The present analysis included the results of testing 10 000 blood samples for viral antibodies between May 9 and June 2, but Canadian Blood Services researchers are still completing their full analysis of 37 800 samples collected during the study period.

Héma-Québec will release the results of a study of 7000 Quebec blood donors in the next few weeks, which Hankins says will be important for a complete national picture.

But blood donors are not necessarily representative of Canada’s population since they tend to be young (aged 17–70), healthy, urban, and exclude people in the North, Hankins emphasized.

To get a clearer picture of national seroprevalence, the task force has teamed up with other research groups to round out the picture of the spread of SARS-CoV-2 in Canada. Initiatives in the pipeline include:

  • A study of specimens from pregnant women left over from rubella and syphilis testing. Hankins says pregnant women are generally representative of the reproductive age group.

  • Adding testing for SARS-CoV-2 antibodies to the Canadian Longitudinal Study on Aging. Begun about 10 years ago, this national, long-term study of more than 50 000 adults who were aged 45 to 85 at recruitment will follow participants until 2033 or death.

  • A study of 15 000 Indigenous people.

  • A household study, representative of the entire country, conducted by Statistics Canada. This study will depend on validating the use of dried blood spots as specimens, which participants can collect themselves. Hankins says validation should be completed by the end of August, so the study may begin in September and wrap up by the end of the year.

The task force also plans to test three other groups for antibodies — children, occupational groups such as health workers, and patients who have had COVID-19. Hankins notes that the last group will provide an opportunity to explore another of the task force’s priority areas — understanding SARS-CoV-2 immunity.

Researchers will examine the antibody levels of people who have had COVID-19 over time to see if they wane and if immune markers correlate with disease severity, the presence of lingering symptoms and organ damage after the acute infection has resolved.

When it comes to immunity, almost nothing is clearer now than when the task force was struck, except that the virus is more complicated than anyone expected, Hankins says. Questions persist about the role of antibodies in immunity and what that may mean for the prospects of a vaccine.

Recent studies have shown that patients with COVID-19 can generate an antibody response while still showing substantial viral loads and symptoms of the disease, and some people do not generate a measurable antibody response to infection, but still recover, so it’s possible that other immune functions are involved.

Looking beyond seroprevalence and immunity studies, Canada’s COVID-19 Immunity Task Force will also inform Canada’s federal COVID-19 strategy, including identifying priority recipients when a successful vaccine becomes available and advising on when to lift pandemic restrictions.

The other task force members include co-chair Dr. David Naylor, who authored a report on Canada’s handling of the SARS outbreak in 2003, Dr. Tim Evans of the School of Population and Global Health at McGill University, Canada’s Chief Public Health Officer Dr. Theresa Tam, and Dr. Mona Nemer, chief science advisor to the Prime Minister, Minister of Science and Cabinet.

“We really want the science to drive the policy response,” Hankins says. “We’ve been running as fast as we can. We’re trying to be as nimble as possible and trying to make sure that we’re aware of everything that’s going on.”

Footnotes

  • Posted on cmajnews.com on July 24, 2020

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (32)
CMAJ
Vol. 192, Issue 32
10 Aug 2020
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
More questions than answers as Canada’s immunity task force releases initial results
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
More questions than answers as Canada’s immunity task force releases initial results
Terry Murray
CMAJ Aug 2020, 192 (32) E933-E934; DOI: 10.1503/cmaj.1095887

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
More questions than answers as Canada’s immunity task force releases initial results
Terry Murray
CMAJ Aug 2020, 192 (32) E933-E934; DOI: 10.1503/cmaj.1095887
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • New national consortium to tackle anti-Indigenous racism in medical education
  • Unpacking “long COVID”
  • Health advocates want help handling online harassment
Show more News

Similar Articles

Collections

  • Topics
    • Vaccination
    • Public health
    • Infectious diseases

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire